Ketamine의 속효성 항우울효과와 임상 적용
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김용구 | - |
dc.contributor.author | 신철민 | - |
dc.date.accessioned | 2021-09-02T17:28:48Z | - |
dc.date.available | 2021-09-02T17:28:48Z | - |
dc.date.created | 2021-06-17 | - |
dc.date.issued | 2018 | - |
dc.identifier.issn | 1015-4817 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/78679 | - |
dc.description.abstract | Although the biological causes of depression have been well established, the current use of antidepressants are still mostly based on the monoamine hypothesis of depression. However, monoamine antidepressants delay treatment of depression, and there is the problem of depressed patients who are resistant. Ketamine, a N-methyl-D-aspartate receptor (NMDAR) antagonist, is firstly introduced as an anesthetic. The hypothesis on the mechanism of ketamine as an antidepressant has been proposed through direct NMDAR inhibition, inhibition of γ-aminobutyric acid-ergic interneuron NMDARs and the role of ketamine metabolite (2R,6R)-hydroxynorcetamine (HNK). The ketamine also reverses the lack of synaptic connectivity and neurotrophic factors in depressed states by downstream mechanism of action. Through preclinical trials, there is a growing body of evidence indicating that ketamine has the potential for treatment of depression. In recent clinical studies, ketamine exhibits rapid-acting antidepressants effects and improvement of depression and even suicidality. This review examines current researches on molecular and cellular mechanisms of ketamine as an antidepressant, and reviews the current status of clinical studies, problems, and clinical applicability of ketamine. | - |
dc.language | Korean | - |
dc.language.iso | ko | - |
dc.publisher | 대한신경정신의학회 | - |
dc.title | Ketamine의 속효성 항우울효과와 임상 적용 | - |
dc.title.alternative | Rapid-Acting Antidepressant Effect of Ketamine and Its Clinical Application | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | 김용구 | - |
dc.identifier.doi | 10.4306/jknpa.2018.57.2.108 | - |
dc.identifier.bibliographicCitation | 신경정신의학, v.57, no.2, pp.108 - 118 | - |
dc.relation.isPartOf | 신경정신의학 | - |
dc.citation.title | 신경정신의학 | - |
dc.citation.volume | 57 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 108 | - |
dc.citation.endPage | 118 | - |
dc.type.rims | ART | - |
dc.identifier.kciid | ART002395969 | - |
dc.description.journalClass | 2 | - |
dc.description.journalRegisteredClass | kci | - |
dc.description.journalRegisteredClass | other | - |
dc.subject.keywordAuthor | Ketamine | - |
dc.subject.keywordAuthor | Glutamate | - |
dc.subject.keywordAuthor | N-methyl-D-aspartate receptor | - |
dc.subject.keywordAuthor | Rapid-acting antidepressant | - |
dc.subject.keywordAuthor | Depression. | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.